Cantor Fitzgerald Reaffirms “Buy” Rating for Aridis Pharmaceuticals (ARDS)

Cantor Fitzgerald reissued their buy rating on shares of Aridis Pharmaceuticals (NASDAQ:ARDS) in a report released on Wednesday. Cantor Fitzgerald currently has a $25.00 price target on the stock.

“ARDS is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. We expect upward earnings revisions and multiple expansion to move ARDS’s stock higher. That should be driven by the successful advancement of ARDS’s pipeline. Valuation Summary We used a blend of DCF and EV/EBITDA analyses to arrive at our 12-month PT of $25.”,” Cantor Fitzgerald’s analyst commented.

A number of other research analysts also recently commented on ARDS. Zacks Investment Research raised shares of Aridis Pharmaceuticals from a hold rating to a buy rating and set a $14.00 target price on the stock in a research report on Tuesday, November 13th. ValuEngine downgraded shares of Aridis Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, December 21st. Finally, Maxim Group set a $25.00 target price on shares of Aridis Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, December 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $25.40.

ARDS traded down $0.28 on Wednesday, reaching $9.60. 1,570 shares of the company traded hands, compared to its average volume of 2,763. Aridis Pharmaceuticals has a one year low of $7.59 and a one year high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.92). The business had revenue of $1.02 million for the quarter, compared to analyst estimates of $0.33 million. Research analysts forecast that Aridis Pharmaceuticals will post -3.05 EPS for the current fiscal year.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also: Initial Public Offering (IPO)

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply